4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,927,205 | -2.0% | 308,500 | +39.2% | 1.28% | +33.4% |
| Q2 2023 | $4,006,119 | -25.8% | 221,700 | -29.4% | 0.96% | -40.8% |
| Q1 2023 | $5,397,660 | -26.4% | 314,000 | -4.8% | 1.62% | -36.6% |
| Q4 2022 | $7,329,300 | +159.9% | 330,000 | -5.9% | 2.55% | +118.8% |
| Q3 2022 | $2,820,000 | +24.3% | 350,700 | +7.9% | 1.16% | +13.9% |
| Q2 2022 | $2,269,000 | -53.8% | 325,000 | 0.0% | 1.02% | -33.0% |
| Q1 2022 | $4,914,000 | -2.2% | 325,000 | +41.9% | 1.53% | +43.2% |
| Q4 2021 | $5,024,000 | – | 229,000 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |